A recently published meta-analysis of the clinical efficacy, safety, and pharmacokinetics of anti-tumor necrosis factor (TNF)-alpha biosimilar agents concludes that the biosimilars had an overall comparable efficacy and safety profile compared with their reference agents in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), supporting their use to treat these conditions.
The investigators searched electronic databases (PubMed/MEDLINE, Google Scholar, Scopus, EMBASE, and Cochrane Central Register of Controlled Trials) and abstracts from medical conferences for randomized controlled trials assessing the efficacy and safety of biosimilars of anti-TNF-alpha agents, compared with their reference agents, in patients with a variety of immune-mediated diseases. The analysis used 9 studies encompassing treatment outcomes in 3291 patients with RA and AS who used infliximab (5 studies), adalimumab (2 studies), and etanercept (2 studies).
One primary outcomes of the study was the rate of clinical response and adverse events among patients treated with biosimilars compared with their reference drugs. Risk ratios of American College of Rheumatology 20% (ACR20) and 70% (ACR70) response were calculated for RA patients, and Assessment of SpondyloArthritis International Society 20% (ASAS20) response rates were calculated for AS patients, respectively. Response rates were analyzed at short (12 to 16 weeks), medium (24 to 30 weeks), and long-term (48 to 54 weeks) intervals. The second outcome studied was the occurrence of anti-drug antibodies (immunogenicity) with the use of biosimilars compared with immunogenicity rates to reference agents at short (14 weeks), medium (up to 24 to 30-weeks or at 30 weeks), and long (48 to 54 weeks)-term periods. Immunogenicity is a concern because it can potentially limit clinical efficacy and safety.
The researchers write that their study is the first to comprehensively analyze and combine the available data by meta-analysis. They conclude that their study showed biosimilars of anti-TNF-alpha agents had overall similar clinical efficacy, safety, and immunogenicity compared with their reference agents in RA and AS up to 54 weeks of follow-up. The only exceptions were that biosimilars of infliximab were associated with an increased risk of upper respiratory tract infection and biosimilars of etanercept showed a significantly lower occurrence of anti-drug antibodies.
The authors believe that their study demonstrated that patients with RA and AS treated with biosimilars had no significant differences in the frequency of overall treatment-emergent adverse events, severe treatment-emergent adverse events, infusion reactions, malignancies, and infections compared with their respective reference biologics. “The results of our study support the use of biosimilars in the treatment of RA and AS,” they conclude.
Reference
Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis [published online February 14, 2017]. J Autoimmun. http://dx.doi.org/10.1016/j.jaut.2017.02.003.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.